Factors associated with treatment outcomes among patients with HIV receiving second-line antiretroviral drugs
DOI:
https://doi.org/10.14456/dcj.2025.37Keywords:
people living with HIV, second-line ART, treatment outcomes, viral suppression, adherenceAbstract
This study aims to assess the rate of virological suppression at 1 year and its associated factors among people living with HIV receiving second-line antiretroviral therapy (ART). We conducted a retrospective cross-sectional study of the medical records of second-line ART users with a HIV viral load > 1000 copies/ml. Data were analyzed using descriptive statistics and multiple logistic regression analysis. The results revealed that the proportion of virological suppression among people living with HIV receiving second-line ART at 1 year was 35.9% (95% CI=28.0%-43.8%). Factors significantly associated with viral load below 50 copies/ml were reported, including being aged 25-34 years (ORadj=12.1, 95%CI=1.4-103.4) and 35-49 years (ORadj=9.0, 95%CI=1.2-66.5), switching to second-line ART within less than 30 days (ORadj= 4.5, 95%CI=1.1-18.0), and having good adherence to second-line ART (ORadj=11.0, 95% CI=3.4-35.5). The study results indicate that the quality of health services for people living with HIV should be improved, especially timely switching to second-line ART after virological failure and promoting second-line ART adherence.
Downloads
References
Department of Disease Control (TH). HIV Info HUB [Internet]. Ministry of Public Health. 2562 [cited 2025 Jul 20]. Available from: https://hivhub.ddc.moph.go.th (in Thai)
National Health Security Office (TH). NAP Web Report [Internet]. National Health Security Office [cited 2025 Jul 20]. Available from: https://www.nhso.go.th/th/agency-th/online-service (in Thai)
World Health Organization (WHO). The public health response to pretreatment HIV drug resistance [Internet]. World Health Organization. 2017 [cited 2023 Jul 16]. Available from: https://www.hst.org.za/publications/NonHST%20Publications/The%20Public%20Health%20Response%20to%20Pretreatment%20HIV%20Drug%20Resistance.pdf
Ruxrungtham K, Chokephaibulkit K, Chetchotisakd P, Chariyalertsak S, Kiertburanakul S, Putcharoen O, et al. National guidelines for HIV diagnosis, treatment and prevention, Thailand 2021/2022 [Internet]. Department of Disease Control, Ministry of Public Health (TH). 2022 [cited 2023 Jul 15]. Available from: https://www.thaiaidssociety.org/wp-content/uploads/2023/03/HIV-AIDS-Guideline-2564_2565_ED2.pdf (in Thai)
Ngamjarus C. n4Studies: sample size calculation for an epidemiological study on a smart device. Siriraj Med J. 2016;68(3):160-70 (in Thai)
Wedajo S, Degu G, Deribew A, Ambaw F. Treatment failure, death, and predictors among PLWHIV on second-line antiretroviral therapy in Dessie Comprehensive Specialized Hospital, northeast Ethiopia: a retrospective cohort study. PLoS One. 2022;17(6):e0269235.
May Myat Win, Maek-a-nantawat W, Phonrat B, Kiertiburanakul S, Sungkanuparph S. Virologic and immunologic outcomes of the second-line regimens of antiretroviral therapy among HIV-infected patients in Thailand. J Int Assoc Physicians AIDS Care. 2011;10(1):57-63.
Sudsila P, Teeraananchai S, Kiertiburanakul S, Lertpiriyasuwat C, Triamwichanon R, Gatechompol S, et al. Treatment outcomes after switching to second-line anti-retroviral therapy: results from the Thai National Treatment Program. J Int Assoc Provid AIDS Care. 2023;22:1-11.
Hailu D, Jara D, Edin A, Awol A, Ayele A, Fekadu Y, et al. Viral load suppression and associated factors among HIV-infected patients on second-line antiretroviral therapy at public health facilities of West Guji and Borena zones, Southern Ethiopia: facility-based cross-sectional study. medRxiv [Internet]. 2024 [cited 2025 Feb 20]. Available from: https://doi.org/10.1101/2024.04.02.24305217
Asare K, Sookrajh Y, van der Molen J, Khubone T, Lewis L, Lessells RJ, et al. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study. Lancet Glob Health. 2024;12(2):e282-91.
Nyaboke R, Ramadhani HO, Lascko T, Awuor P, Kirui E, Koech E, et al. Factors associated with adherence and viral suppression among patients on second-line antiretroviral therapy in an urban HIV program in Kenya. SAGE Open Med. 2023;11:1-9.
Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM. Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine (Baltimore). 2016;95(15):e3361.
Wagner Z, Mukasa B, Nakakande J, Stecher C, Saya U, Linnemayr S. Impact of the COVID-19 pandemic on use of HIV care, antiretroviral therapy adherence, and viral suppression: an observational cohort study from Uganda. J Acquir Immune Defic Syndr. 2021;88(5):448-56.
World Health Organization. Policy brief: update of recommendations on first-and second-line antiretroviral regimens [Internet]. World Health Organization. 2019 [cited 2023 Jul 16]. Available from: https://iris.who.int/handle/10665/325892
Wedajo S, Getu D, Amare D, Ambaw F. Rate of viral re-suppression and retention to care among PLHIV on second-line antiretroviral therapy at Dessie Comprehensive Specialized Hospital, Northeast Ethiopia: a retrospective cohort study. HIV AIDS (Auckl). 2021;13:877-87.
Ramadhani HO, Bartlett JA, Thielman NM, Pence BW, Kimani SM, Maro VP, et al. Association of first-line and second-line antiretroviral therapy adherence. Open Forum Infect Dis. 2014;1(2):ofu079.
Shushtari ZJ, Salimi Y, Sajjadi H, Paykani T. Effect of social support interventions on adherence to antiretroviral therapy among people living with HIV: a systematic review and meta-analysis. AIDS Behav. 2023;27(5): 1619-35.
Musayón-Oblitas Y, Crcamo C, Gimbel S. Counseling for improving adherence to antiretroviral treatment: a systematic review. AIDS Care. 2018;31(1):4-13.
Bonner K, Mezochow A, Roberts T, Ford N, Cohn J. Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr. 2013;64(1):74-8.
Kroidl A, Burger T, Urio A, Mugeniwalwo R, Mgaya J, Mlagalila F, et al. High turnaround times and low viral resuppression rates after reinforced adherence counselling following a confirmed virological failure diagnostic algorithm in HIV-infected patients on first-line antiretroviral therapy from Tanzania. Trop Med Int Health. 2020;25(5):579-89.
Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, Wood R. Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out program in South Africa. Antivir Ther. 2011;16(6):853-61.
Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014-July 2015. BMC Infect Dis. 2017;17(1):326.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Disease Control Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the Disease Control Journal are considered as academic work, research or analysis of the personal opinion of the authors, not the opinion of the Thailand Department of Disease Control or editorial team. The authors must be responsible for their articles.
